MEMBERS

If you are a member of the network, please log in to access Network content and tools. If you do not have a username, contact your site principal investigator or site coordinator and request that they complete a membership request for you. If you have forgotten your password, you may CLICK HERE.


AS ATN

You are here

Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial

TitleMetformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial
Publication TypeJournal Article
Year of Publication2016
AuthorsAnagnostou, E, Aman, MG, Handen, BL, Sanders, KB, Shui, AM, Hollway, JA, Brian, J, L Arnold, E, Capano, L, Hellings, JA, ,
JournalJAMA Psychiatry
Volume73
Pagination928–937
Summary

Lead Author
Evdokia Anagnostou

Study Aims and Objectives
To evaluate how well Metformin, a common diabetes drug, works to reduce weight gain caused by medications taken by young people with Autism Spectrum Disorder (ASD).

Methods - Sample, Procedure, Study Measures, Analysis
60 boys and girls with ASD were given either Metformin or a placebo for 16 weeks. Experimenters monitored participant body mass index (BMI), as well as metabolism.

Results – Main Finding(s)
The participants who took metformin gained less weight than those who took the placebo. The taking of Metformin resulted in little change to the subjects’ metabolism when compared to the placebo group. Furthermore, those who took metformin showed decreased BMI.

Conclusion – Summary Statement
Metformin may be effective in decreasing weight gain caused by medications taken by children with ASD. Additionally, the drug was well tolerate by the those participating in the study, resulting in few negative side effects.

PubMed ID27556593